USRE36011E - Protein separations by capillary electrophoresis using amino acid-containing buffers - Google Patents
Protein separations by capillary electrophoresis using amino acid-containing buffers Download PDFInfo
- Publication number
- USRE36011E USRE36011E US08/975,179 US97517997A USRE36011E US RE36011 E USRE36011 E US RE36011E US 97517997 A US97517997 A US 97517997A US RE36011 E USRE36011 E US RE36011E
- Authority
- US
- United States
- Prior art keywords
- capillary
- accordance
- amino acid
- buffer
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 26
- 239000000872 buffer Substances 0.000 title abstract description 33
- 238000005251 capillar electrophoresis Methods 0.000 title abstract description 6
- 238000000926 separation method Methods 0.000 title description 21
- 239000000203 mixture Substances 0.000 claims abstract description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 27
- 229940024606 amino acid Drugs 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 24
- 235000018102 proteins Nutrition 0.000 claims description 23
- 239000004471 Glycine Substances 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 229960002449 glycine Drugs 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 8
- 239000005350 fused silica glass Substances 0.000 claims description 7
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 229960003767 alanine Drugs 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 229940063013 borate ion Drugs 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 229960003136 leucine Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229960002898 threonine Drugs 0.000 claims description 6
- 229960004295 valine Drugs 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- 230000005684 electric field Effects 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 229960002429 proline Drugs 0.000 claims description 4
- 229960001153 serine Drugs 0.000 claims description 4
- 239000006172 buffering agent Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 229940085991 phosphate ion Drugs 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 229940049906 glutamate Drugs 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002743 glutamine Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims 5
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 description 34
- 238000005515 capillary zone electrophoresis Methods 0.000 description 19
- 238000001962 electrophoresis Methods 0.000 description 19
- 239000012146 running buffer Substances 0.000 description 16
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000001502 gel electrophoresis Methods 0.000 description 11
- 102000009027 Albumins Human genes 0.000 description 10
- 108010088751 Albumins Proteins 0.000 description 10
- 230000005012 migration Effects 0.000 description 9
- 238000013508 migration Methods 0.000 description 9
- 239000007982 barbital buffer Substances 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 108010044091 Globulins Proteins 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 208000002774 Paraproteinemias Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000326 densiometry Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 3
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005370 electroosmosis Methods 0.000 description 2
- -1 pentafluorobenzoyl groups Chemical group 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 206010033264 Ovarian hyperfunction Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001337 aliphatic alkines Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000006564 estrogen excess Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44747—Composition of gel or of carrier mixture
Definitions
- This invention resides in the field of electrophoresis of proteins, and addresses methods for achieving high resolution in protein separations by capillary electrophoresis.
- Analyses of the levels of proteins in mammalian serum are widely used as indications of various diseases and abnormal physiological conditions.
- a subnormal level of albumin for example, is an indication of renal disease, while high albumin is a characteristic of dehydration.
- an elevated level of pre- ⁇ lipoprotein can be an indication of chronic alcoholism or of hyperestrogenism, and elevated levels of ⁇ -lipoprotein can be indicative of high cholesterol.
- the electrokinetic potential at the capillary wall surface is a prominent factor in the movement and separation of the proteins upon imposition of the electric field. This movement and separation can be changed by the interactions between the proteins and the capillary wall. Separations run at high or low pH, which place a net charge on the proteins, may minimize the interaction between the proteins and the capillary wall. These interactions are particularly strong in capillaries made of fused silica, causing adsorption of the proteins at the capillary wall. The adsorption has an influence on the electroosmotic flow by changing the charge density of the wall surface. Changes in the electroosmotic flow in turn cause changes in migration times, peak resolution and reproducibility. These considerations also apply, although often to a lesser extent, in slab electrophoresis, particularly with the use of thin slabs.
- Efforts to improve the separation by suppressing the interaction between the proteins and the capillary wall or other wall enclosing the separation zone have resulted in the development of a variety of treatments, additives and operating conditions.
- One technique is to use a buffer having a pH that is higher than the isoelectric points of the sample proteins, thereby imparting a net negative charge to the proteins to repel them from the negatively charged wall.
- a disadvantage of this method is the risk of hydrolysis and other structural changes in the proteins. Strongly basic buffers with high salt concentrations have also been used as a means of blocking ionic interactions between the proteins and the wall. High salt concentrations however increase the conductivity of the buffer and hence the rate of heat generation inside the capillary.
- a further alternative has been to coat the wall to mask or neutralize the potential, and coatings for this purpose have included polyacrylamide, glycol, and pentafluorobenzoyl groups. Disadvantages of coated walls include low reproducibility due to the gradual deterioration of the coating over repeated use, and a reduction in the speed of the analysis due to the elimination of the electroendosmotic flow component.
- a still further alternative has been the inclusion of borate ion in the running buffer to form complexes with the the sugar moieties of glycoproteins and thereby neutralize their charge.
- borate ion entails a risk of denaturing certain proteins, particularly immunoglobulins, and thereby creating a separate peak. Also, borate ion increases the conductivity of the buffer, limiting the electric field and the speed with which the separation can be achieved.
- the amino acid-containing buffer is used in the pretreatment of the capillary or other electrophoretic cell prior to insertion of the sample, as a diluting buffer for the sample as it is inserted, and as the electrode buffers in each of the two electrode reservoirs which complete the electrical circuit between the voltage source and the separation region.
- the amino acids reduce both protein-wall interactions and protein-protein interactions, and avoid the risk of denaturation. Separations performed with buffers according to this invention will therefore provide the same or an equivalent separation as those achieved by slab gel electrophoresis, with high precision, high resolution and reproducibility.
- FIG. 1 is an electropherogram of a normal serum sample analyzed by capillary zone electrophoresis using a buffer of the present invention.
- FIG. 2a is an electropherogram of a normal serum sample analyzed by capillary zone electrophoresis using a buffer of the present invention, using a different set of operating conditions from those of FIG. 1.
- FIG. 2b is a densitometry scan of the same serum sample as FIG. 2a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
- FIG. 3a is an electropherogram of a serum sample from a subject with monoclonal gammopathy, using capillary zone electrophoresis with a buffer of the present invention.
- FIG. 3b is a densitometry scan of the same serum sample as FIG. 3a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
- FIG. 4a is an electropherogram of a serum sample from a subject with polyclonal gammopathy, using capillary zone electrophoresis with a buffer of the present invention.
- FIG. 4b is a densitometry scan of the same serum sample as FIG. 4a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
- FIG. 5a is an electropherogram of a serum sample from a subject with IgA monoclonal gammopathy with normal IgG, using capillary zone electrophoresis with a buffer of the present invention.
- FIG. 5b is a densitometry scan of the same serum sample as FIG. 5a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
- FIG. 6a is an electropherogram of a serum sample from a subject with biclonal or oligoclonal gammopathy with elevated ⁇ 1 and ⁇ 2 , using capillary zone electrophoresis with a buffer of the present invention.
- FIG. 6b is a densitometry scan of the same serum sample as FIG. 6a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
- FIG. 7a is an electropherogram of a serum sample from a subject with minimonoclonal gammopathy, using capillary zone electrophoresis with a buffer of the present invention.
- FIG. 7b is a densitometry scan of the same serum sample as FIG. 7a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
- FIG. 8a is a correlation plot of albumin peak areas obtained by capillary zone electrophoresis with a buffer of the present invention and those obtained by slab gel electrophoresis using a buffer outside the scope of this invention.
- FIG. 8b is a correlation plot analogous to that of FIG. 8a for ⁇ 1 globulin peak areas.
- FIG. 8c is a comparison plot analogous to that of FIG. 8a for ⁇ 2 globulin peak areas.
- FIG. 8d is a comparison plot analogous to that of FIG. 8a for ⁇ globulin peak areas.
- FIG. 8e is a comparison plot analogous to that of FIG. 8a for ⁇ globulin peak areas.
- Amino acids are effective in this invention by virtue of their negative charge at high pH due to the ionization of the carboxyl group (--COO - ).
- Useful amino acids include both the essential and nonessential amino acids. Examples of some of the more prominent amino acids are glycine, alanine, valine, leucine, isoleucine, serine, threonine, proline, aspartate, glutamate, arginine, threonine and glutamine. Preferred among these are glycine, alanine, valine, leucine, isoleucine, serine, threonine and proline, with the more preferred being glycin, alanine, valine, leucine and isoleucine.
- a preferred class of amino acids are ⁇ -amino acids, and particularly those that have a relatively low conductivity in aqueous solution, such as glycine. Two or more amino acids may be used in a single buffer solution rather than just one, although in most cases a single amino acid will suffice.
- the concentration of the amino acid is not critical, and the optimal concentration in any particular case may vary depending on such factors as the dilution of the sample being analyzed and the nature of the capillary, both in terms of any surface treatments which may have been applied and its inner diameter. In general, best results are obtained with amino acid concentrations within the range of about 10 mM to about 500 mM, and preferably about 20 mM to about 200 mM.
- the buffer is preferably an aqueous solution, although not necessarily limited to any particular solvent.
- the solution is alkine to impose a negative charge on the amino acid. While the degree of alkalinity may vary, preferred solutions are those with pH within the range of about 8 to about 11, and most preferably about 9 to about 10.
- Samples to be analyzed by the method of this invention are preferably diluted with the buffer prior to being injected into or loaded on the column.
- the degree of dilution is not critical and may vary. Best results will generally be achieved, however, with dilutions of 1 part sample to a range of from about 1 part to about 100 parts of the buffer solution, and preferably 1 part sample to a range of from about 3 parts to about 30 parts of the buffer solution.
- the invention has application to liquid samples of protein mixtures in general, with particular utility when used for the analysis of samples of biological fluids.
- biological fluids examples include urine, saliva, cerebrospinal fluid, whole blood, plasma and serum. Serum samples are of particular interest.
- the buffer solution may contain further additives.
- Salts for example, may be included to increase the ionic strength of the solution for purposes of enhancing the resolution of the separated protein zones.
- Preferred salts are inorganic salts, such as halides of alkaline and alkaline earth metals. Examples are sodium and potassium halides, such as chloride, iodide, bromide and fluoride, with sodium chloride preferred.
- the concentration of the salt is not critical and can vary, with optimal ranges depending on the other variables of the system. A typical range is from about 1 mM to about 100 nM, and preferably from about 10 mM to about 30 mM.
- the buffer solution contain no other buffering agents than the amino acid. It is further preferred that the buffer solution contain no additives which form complexes or otherwise bind or interact with the proteins or the capillary wall.
- the buffer preferably does not include borate ion, phosphate ion, or substituted analogs of either borate or phosphate ion. Nevertheless, benefits of the invention can still be attained even if these additives are present.
- the invention likewise offers benefits of improved performance in capillaries of a variety of materials, with or without coatings.
- the invention is of particular interest in capillaries of silica-containing materials such as fused silica, glass or quartz, and most particularly silica-containing capillaries whose internal wall surfaces are uncoated.
- Protein separations in accordance with the present invention are readily performed with equipment, materials, operating conditions and procedures used in conventional electrophoretic separations.
- Preferred capillaries are those having internal diameters of less than about 200 microns, and most preferably about 10 microns to about 100 microns.
- the invention is also applicable to electrophoretic separations performed in slab-shaped cells and other non-capillary systems.
- voltages of at least about 50 volts per centimeter length of the capillary are preferred, with a voltage range of about 100 volts/cm to about 1000 volts/cm particularly preferred.
- a running buffer was prepared by dissolving 25 mM glycine and 25 mM NaCl in deionized water and adjusting the pH to 11 with 1N NaOH.
- a fused silica capillary measuring 50 ⁇ , inside diameter, with an outside diameter of 375 ⁇ and a 25 cm total length (20 cm from the inlet to the detector) was used.
- the inside surface of the capillary was uncoated, while the outside surface was coated with polyimide to improve flexibility and resist breakage.
- the capillary was preconditioned by washing for 2 minutes with 1N NaOH, rinsing for 2 minutes with distilled water, and washing for 5 minutes with the running buffer.
- the capillary was then conditioned by passing 20 kV through the capillary for 2 hours while filled with the running buffer.
- Drug-free (normal) serum was diluted 50 times with the running buffer, then injected into the capillary by pressure at 2 psi (0.14 kg/cm 2 ) for 1 second. Electrophoresis was then run at a voltage of 15.00 kV with detection by absorptivity at a wavelength of 214 mm. Five peaks appeared within three minutes, as shown by the electropherogram in FIG. 1. The peaks represent, from left to right, the ⁇ (gamma) globulin fraction, the ⁇ (beta) globulin fraction, the ⁇ 1 (alpha-1) globulin fraction, the ⁇ 2 (alpha-2) globulin fraction, and the albumin fraction. The peaks are well-defined with a steady baseline.
- This example uses a buffer solution of the present invention to compare electropherograms of serum samples from human subjects with various diseases, and also includes electropherograms taken on agarose gels without the presence of amino add.
- the amino acid running buffer was prepared by dissolving 11.26 g of glycine and 0.76 g NaCl in 800 mL distilled water, adjusting the pH of the solution to 9.6 with 1N NaOH, then bringing the final volume to 1000 mL with deionized water and passing the resulting solution through a 0.5 ⁇ filter.
- the resulting running buffer contained 150 mM glycine.
- the serum samples were prepared by mixing one part sample with nine parts running buffer (volume basis).
- the capillary was fused silica with an inside diameter of 25 ⁇ and an outside diameter of 360 ⁇ , with a length of 24 cm, of which 19 cm was the distance from inlet to detector.
- the interior surface of the capillary was uncoated, while the outer surface was coated with polyimide.
- the capillary was prepared by washing with 1N NaOH for 30 seconds, followed by a rinse of 30 seconds with the running buffer.
- Capillary zone electrophoresis (using the running buffer alone as the separation medium) was conducted at a temperature of 20° C., with a sample injection of 5 psi (0.35 kg/cm 2 ) for one second, and a run voltage of 15 kV at 16 ⁇ Ampere for three minutes, and detection at 214 nm.
- the comparison tests were performed in pre-cast agarose slab gels, using barbital buffer.
- the buffer composition was 10 mM 5,5-diethylbarbituric acid plus 50 mM 5,5-diethylbarbituric add sodium salt, with a pH of 8.6 and a voltage of 100 V, using blue stain to render the protein visible.
- electropherogram traces are shown in individual figures as follows:
- FIG. 2a normal serum using capillary zone electrophoresis with glycine running buffer
- FIG. 2b normal serum using agarose slab gel with barbital buffer
- FIG. 3a serum from subject with monoclonal gammopathy, using capillary zone electrophoresis with glycine running buffer
- FIG. 3b serum from subject with monoclonal gammopathy, using agarose slab gel with barbital buffer
- FIG. 4a serum from subject with polyclonal gammopathy, using capillary zone electrophoresis with glycine running buffer
- FIG. 4b serum from subject with polyclonal gammopathy, using agarose slab gel with barbital buffer
- FIG. 5a serum from subject with IgA monoclonal gammopathy with normal IgG, using capillary zone electrophoresis with glycine running buffer
- FIG. 5b serum from subject with IgA monoclonal gammopathy with normal IgG, using agarose slab gel with barbital buffer
- FIG. 6a serum from subject with biclonal or oligoclonal gammopathy with elevated ⁇ 1 and ⁇ 2 , using capillary zone electrophoresis with glycine running buffer
- FIG. 6b serum from subject with biclonal or oligoclonal gammopathy with elevated ⁇ 1 and ⁇ 2 , using agarose slab gel with barbital buffer
- FIG. 7a serum from subject with minimonoclonal gammopathy, using capillary zone electrophoresis with glycine running buffer
- FIG. 7b serum from subject with minimonoclonal gammopathy, using agarose slab gel with barbital buffer
- the peaks shown in all of these electropherograms are albumin and the fractions ⁇ 1 , ⁇ 2 , ⁇ and ⁇ , in that order, from right to left in the capillary zone electrophoresis traces, and from left to right in the slab gel electrophoresis traces, albumin being the largest peak in each case.
- the two leftmost peaks are IgG and IgA, respectively, as are the two rightmost peaks in FIG. 5b.
- the traces show that the peaks were separated as effectively in the capillary zone electrophoresis traces with the glycine buffer as they were in the slab gel electrophoresis traces with the barbital buffer.
- This example reports a correlation study in which serum samples from 37 different patients were analyzed by the two methods described in Example 2. Comparisons of the areas under the peaks were made between the two methods for each of the five components, the areas having been determined by integrators. Regression analyses were also performed. The results are plotted in FIGS. 8a, 8b, 8c, 8d and 8e, for the albumin, ⁇ 1 , ⁇ and ⁇ fractions, respectively.
- the regression analyses produced the following:
- the correlation for the ⁇ zone (FIG. 8d) is not as good as the correlations for the other four zones. There are two possible reasons. First the ⁇ 2 -globulin may bind to dye with high affinity but with low UV absorbance. Second, the auto-delimiting on the densitometer was not consistent. The correlations for the other four zones however are convincing evidence that the capillary zone electrophoresis method with glycine buffer is an effective means of achieving proper separation of the proteins in the serum samples.
- This example is a study of the reproducibility of results from repeated electrophoretic separations of a single serum sample.
- Six capillaries were used, and ten runs were performed in each capillary in consecutive manner without intervening treatments of the capillaries, under the conditions described in Example 2. Migration times and peak areas were measured in each electropherogram for each of the five peaks plus an internal standard. The mean values were then calculated for each series of ten runs in a run-to-run comparison for each capillary, and standard deviations and coefficients of variation (the standard deviation divided by the mean) were determined. The results are listed in Tables I and II, where "S.D.” denotes the standard deviation, and "%C.V.” the coefficient of variation expressed as a percent.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Protein mixtures are separated by capillary electrophoresis in a buffer containing one or more amino acids in an amount sufficient to prevent or substantially reduce the degree of protein binding to the wall of the capillary.
Description
This invention resides in the field of electrophoresis of proteins, and addresses methods for achieving high resolution in protein separations by capillary electrophoresis.
Analyses of the levels of proteins in mammalian serum are widely used as indications of various diseases and abnormal physiological conditions. A subnormal level of albumin, for example, is an indication of renal disease, while high albumin is a characteristic of dehydration. Similarly, an elevated level of pre-β lipoprotein can be an indication of chronic alcoholism or of hyperestrogenism, and elevated levels of β-lipoprotein can be indicative of high cholesterol.
Proteins are readily separated by electrophoresis, and both slab gel electrophoresis and capillary electrophoresis have been used. The advantage of capillary electrophoresis is that very small samples can be analyzed, and because of the high wall surface-to-volume ratio in a capillary the heat generated by the electric current is rapidly dissipated, which permits separations to be peformed at high voltages and therefore shorter separation times. Open capillary zone electrophoresis, in which the separation medium is a buffer solution, is particularly useful since the capillary can be easily conditioned and filled with the solution for each use.
The electrokinetic potential at the capillary wall surface is a prominent factor in the movement and separation of the proteins upon imposition of the electric field. This movement and separation can be changed by the interactions between the proteins and the capillary wall. Separations run at high or low pH, which place a net charge on the proteins, may minimize the interaction between the proteins and the capillary wall. These interactions are particularly strong in capillaries made of fused silica, causing adsorption of the proteins at the capillary wall. The adsorption has an influence on the electroosmotic flow by changing the charge density of the wall surface. Changes in the electroosmotic flow in turn cause changes in migration times, peak resolution and reproducibility. These considerations also apply, although often to a lesser extent, in slab electrophoresis, particularly with the use of thin slabs.
Efforts to improve the separation by suppressing the interaction between the proteins and the capillary wall or other wall enclosing the separation zone have resulted in the development of a variety of treatments, additives and operating conditions. One technique is to use a buffer having a pH that is higher than the isoelectric points of the sample proteins, thereby imparting a net negative charge to the proteins to repel them from the negatively charged wall. A disadvantage of this method is the risk of hydrolysis and other structural changes in the proteins. Strongly basic buffers with high salt concentrations have also been used as a means of blocking ionic interactions between the proteins and the wall. High salt concentrations however increase the conductivity of the buffer and hence the rate of heat generation inside the capillary. A further alternative has been to coat the wall to mask or neutralize the potential, and coatings for this purpose have included polyacrylamide, glycol, and pentafluorobenzoyl groups. Disadvantages of coated walls include low reproducibility due to the gradual deterioration of the coating over repeated use, and a reduction in the speed of the analysis due to the elimination of the electroendosmotic flow component. A still further alternative has been the inclusion of borate ion in the running buffer to form complexes with the the sugar moieties of glycoproteins and thereby neutralize their charge. The use of borate ion entails a risk of denaturing certain proteins, particularly immunoglobulins, and thereby creating a separate peak. Also, borate ion increases the conductivity of the buffer, limiting the electric field and the speed with which the separation can be achieved.
It has now been discovered that effective and rapid protein separations can be achieved by capillary electrophoresis without the detrimental characteristics of protein-wall interactions, by using an alkaline run buffer containing an amino acid. Such a buffer is useful in electrophoresis in general, including various electrophoretic cell geometries, but is of particular interest with electrophoresis performed in capillaries. Capillaries of silica-containing material, particularly fused silica whose internal surface has not been coated, are preferred.
In optimal usage, the amino acid-containing buffer is used in the pretreatment of the capillary or other electrophoretic cell prior to insertion of the sample, as a diluting buffer for the sample as it is inserted, and as the electrode buffers in each of the two electrode reservoirs which complete the electrical circuit between the voltage source and the separation region. The amino acids reduce both protein-wall interactions and protein-protein interactions, and avoid the risk of denaturation. Separations performed with buffers according to this invention will therefore provide the same or an equivalent separation as those achieved by slab gel electrophoresis, with high precision, high resolution and reproducibility.
These and other features and advantages of the invention will become more apparent from the description that follows.
FIG. 1 is an electropherogram of a normal serum sample analyzed by capillary zone electrophoresis using a buffer of the present invention.
FIG. 2a is an electropherogram of a normal serum sample analyzed by capillary zone electrophoresis using a buffer of the present invention, using a different set of operating conditions from those of FIG. 1.
FIG. 2b is a densitometry scan of the same serum sample as FIG. 2a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
FIG. 3a is an electropherogram of a serum sample from a subject with monoclonal gammopathy, using capillary zone electrophoresis with a buffer of the present invention.
FIG. 3b is a densitometry scan of the same serum sample as FIG. 3a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
FIG. 4a is an electropherogram of a serum sample from a subject with polyclonal gammopathy, using capillary zone electrophoresis with a buffer of the present invention.
FIG. 4b is a densitometry scan of the same serum sample as FIG. 4a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
FIG. 5a is an electropherogram of a serum sample from a subject with IgA monoclonal gammopathy with normal IgG, using capillary zone electrophoresis with a buffer of the present invention.
FIG. 5b is a densitometry scan of the same serum sample as FIG. 5a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
FIG. 6a is an electropherogram of a serum sample from a subject with biclonal or oligoclonal gammopathy with elevated α1 and α2, using capillary zone electrophoresis with a buffer of the present invention.
FIG. 6b is a densitometry scan of the same serum sample as FIG. 6a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
FIG. 7a is an electropherogram of a serum sample from a subject with minimonoclonal gammopathy, using capillary zone electrophoresis with a buffer of the present invention.
FIG. 7b is a densitometry scan of the same serum sample as FIG. 7a analyzed by slab gel electrophoresis using a buffer outside the scope of this invention.
FIG. 8a is a correlation plot of albumin peak areas obtained by capillary zone electrophoresis with a buffer of the present invention and those obtained by slab gel electrophoresis using a buffer outside the scope of this invention.
FIG. 8b is a correlation plot analogous to that of FIG. 8a for α1 globulin peak areas.
FIG. 8c is a comparison plot analogous to that of FIG. 8a for α2 globulin peak areas.
FIG. 8d is a comparison plot analogous to that of FIG. 8a for β globulin peak areas.
FIG. 8e is a comparison plot analogous to that of FIG. 8a for γ globulin peak areas.
Amino acids are effective in this invention by virtue of their negative charge at high pH due to the ionization of the carboxyl group (--COO-). Useful amino acids include both the essential and nonessential amino acids. Examples of some of the more prominent amino acids are glycine, alanine, valine, leucine, isoleucine, serine, threonine, proline, aspartate, glutamate, arginine, threonine and glutamine. Preferred among these are glycine, alanine, valine, leucine, isoleucine, serine, threonine and proline, with the more preferred being glycin, alanine, valine, leucine and isoleucine. A preferred class of amino acids are α-amino acids, and particularly those that have a relatively low conductivity in aqueous solution, such as glycine. Two or more amino acids may be used in a single buffer solution rather than just one, although in most cases a single amino acid will suffice.
The concentration of the amino acid is not critical, and the optimal concentration in any particular case may vary depending on such factors as the dilution of the sample being analyzed and the nature of the capillary, both in terms of any surface treatments which may have been applied and its inner diameter. In general, best results are obtained with amino acid concentrations within the range of about 10 mM to about 500 mM, and preferably about 20 mM to about 200 mM.
The buffer is preferably an aqueous solution, although not necessarily limited to any particular solvent. The solution is alkine to impose a negative charge on the amino acid. While the degree of alkalinity may vary, preferred solutions are those with pH within the range of about 8 to about 11, and most preferably about 9 to about 10.
Samples to be analyzed by the method of this invention are preferably diluted with the buffer prior to being injected into or loaded on the column. The degree of dilution is not critical and may vary. Best results will generally be achieved, however, with dilutions of 1 part sample to a range of from about 1 part to about 100 parts of the buffer solution, and preferably 1 part sample to a range of from about 3 parts to about 30 parts of the buffer solution.
The invention has application to liquid samples of protein mixtures in general, with particular utility when used for the analysis of samples of biological fluids. Examples of such fluids are urine, saliva, cerebrospinal fluid, whole blood, plasma and serum. Serum samples are of particular interest.
The buffer solution may contain further additives. Salts, for example, may be included to increase the ionic strength of the solution for purposes of enhancing the resolution of the separated protein zones. Preferred salts are inorganic salts, such as halides of alkaline and alkaline earth metals. Examples are sodium and potassium halides, such as chloride, iodide, bromide and fluoride, with sodium chloride preferred. The concentration of the salt is not critical and can vary, with optimal ranges depending on the other variables of the system. A typical range is from about 1 mM to about 100 nM, and preferably from about 10 mM to about 30 mM.
It is also preferred that the buffer solution contain no other buffering agents than the amino acid. It is further preferred that the buffer solution contain no additives which form complexes or otherwise bind or interact with the proteins or the capillary wall. In particular, the buffer preferably does not include borate ion, phosphate ion, or substituted analogs of either borate or phosphate ion. Nevertheless, benefits of the invention can still be attained even if these additives are present.
The invention likewise offers benefits of improved performance in capillaries of a variety of materials, with or without coatings. As noted above, however, the invention is of particular interest in capillaries of silica-containing materials such as fused silica, glass or quartz, and most particularly silica-containing capillaries whose internal wall surfaces are uncoated.
Protein separations in accordance with the present invention are readily performed with equipment, materials, operating conditions and procedures used in conventional electrophoretic separations. Preferred capillaries are those having internal diameters of less than about 200 microns, and most preferably about 10 microns to about 100 microns. The invention is also applicable to electrophoretic separations performed in slab-shaped cells and other non-capillary systems. For capillary systems, voltages of at least about 50 volts per centimeter length of the capillary are preferred, with a voltage range of about 100 volts/cm to about 1000 volts/cm particularly preferred.
The following examples are offered strictly for purposes of illustration, and are intended neither to define nor to limit the invention in any manner.
A running buffer was prepared by dissolving 25 mM glycine and 25 mM NaCl in deionized water and adjusting the pH to 11 with 1N NaOH. A fused silica capillary measuring 50μ, inside diameter, with an outside diameter of 375μ and a 25 cm total length (20 cm from the inlet to the detector) was used. The inside surface of the capillary was uncoated, while the outside surface was coated with polyimide to improve flexibility and resist breakage. The capillary was preconditioned by washing for 2 minutes with 1N NaOH, rinsing for 2 minutes with distilled water, and washing for 5 minutes with the running buffer. The capillary was then conditioned by passing 20 kV through the capillary for 2 hours while filled with the running buffer.
Drug-free (normal) serum was diluted 50 times with the running buffer, then injected into the capillary by pressure at 2 psi (0.14 kg/cm2) for 1 second. Electrophoresis was then run at a voltage of 15.00 kV with detection by absorptivity at a wavelength of 214 mm. Five peaks appeared within three minutes, as shown by the electropherogram in FIG. 1. The peaks represent, from left to right, the γ (gamma) globulin fraction, the β (beta) globulin fraction, the α1 (alpha-1) globulin fraction, the α2 (alpha-2) globulin fraction, and the albumin fraction. The peaks are well-defined with a steady baseline.
This example uses a buffer solution of the present invention to compare electropherograms of serum samples from human subjects with various diseases, and also includes electropherograms taken on agarose gels without the presence of amino add.
The amino acid running buffer was prepared by dissolving 11.26 g of glycine and 0.76 g NaCl in 800 mL distilled water, adjusting the pH of the solution to 9.6 with 1N NaOH, then bringing the final volume to 1000 mL with deionized water and passing the resulting solution through a 0.5μ filter. The resulting running buffer contained 150 mM glycine. The serum samples were prepared by mixing one part sample with nine parts running buffer (volume basis). The capillary was fused silica with an inside diameter of 25μ and an outside diameter of 360μ, with a length of 24 cm, of which 19 cm was the distance from inlet to detector. The interior surface of the capillary was uncoated, while the outer surface was coated with polyimide. The capillary was prepared by washing with 1N NaOH for 30 seconds, followed by a rinse of 30 seconds with the running buffer. Capillary zone electrophoresis (using the running buffer alone as the separation medium) was conducted at a temperature of 20° C., with a sample injection of 5 psi (0.35 kg/cm2) for one second, and a run voltage of 15 kV at 16 μAmpere for three minutes, and detection at 214 nm.
The comparison tests were performed in pre-cast agarose slab gels, using barbital buffer. The buffer composition was 10 mM 5,5-diethylbarbituric acid plus 50 mM 5,5-diethylbarbituric add sodium salt, with a pH of 8.6 and a voltage of 100 V, using blue stain to render the protein visible.
The electropherogram traces are shown in individual figures as follows:
FIG. 2a: normal serum using capillary zone electrophoresis with glycine running buffer
FIG. 2b: normal serum using agarose slab gel with barbital buffer
FIG. 3a: serum from subject with monoclonal gammopathy, using capillary zone electrophoresis with glycine running buffer
FIG. 3b: serum from subject with monoclonal gammopathy, using agarose slab gel with barbital buffer
FIG. 4a: serum from subject with polyclonal gammopathy, using capillary zone electrophoresis with glycine running buffer
FIG. 4b: serum from subject with polyclonal gammopathy, using agarose slab gel with barbital buffer
FIG. 5a: serum from subject with IgA monoclonal gammopathy with normal IgG, using capillary zone electrophoresis with glycine running buffer
FIG. 5b: serum from subject with IgA monoclonal gammopathy with normal IgG, using agarose slab gel with barbital buffer
FIG. 6a: serum from subject with biclonal or oligoclonal gammopathy with elevated α1 and α2, using capillary zone electrophoresis with glycine running buffer
FIG. 6b: serum from subject with biclonal or oligoclonal gammopathy with elevated α1 and α2, using agarose slab gel with barbital buffer
FIG. 7a: serum from subject with minimonoclonal gammopathy, using capillary zone electrophoresis with glycine running buffer
FIG. 7b: serum from subject with minimonoclonal gammopathy, using agarose slab gel with barbital buffer
The peaks shown in all of these electropherograms, with the exception of FIGS. 5a and 5b, are albumin and the fractions α1, α2, β and γ, in that order, from right to left in the capillary zone electrophoresis traces, and from left to right in the slab gel electrophoresis traces, albumin being the largest peak in each case. In FIG. 5a, the two leftmost peaks (at retention times of 1.16 and 124, respectively) are IgG and IgA, respectively, as are the two rightmost peaks in FIG. 5b. The traces show that the peaks were separated as effectively in the capillary zone electrophoresis traces with the glycine buffer as they were in the slab gel electrophoresis traces with the barbital buffer.
This example reports a correlation study in which serum samples from 37 different patients were analyzed by the two methods described in Example 2. Comparisons of the areas under the peaks were made between the two methods for each of the five components, the areas having been determined by integrators. Regression analyses were also performed. The results are plotted in FIGS. 8a, 8b, 8c, 8d and 8e, for the albumin, α1, αand γ fractions, respectively.
The regression analyses produced the following:
FIG. 8a: y=0.9836x+2.4469; R2 =0.9176
FIG. 8b: y=1.5197x+0.2363; R2 =0.9223s
FIG. 8c: y=0.8888x-0.0989; R2 =0.8931
FIG. 8d: y=4147x+2.3944; R2 =0.4587
FIG. 8e: y=1.0696x-0.4784; R2 =0.9789
The correlation for the β zone (FIG. 8d) is not as good as the correlations for the other four zones. There are two possible reasons. First the β2 -globulin may bind to dye with high affinity but with low UV absorbance. Second, the auto-delimiting on the densitometer was not consistent. The correlations for the other four zones however are convincing evidence that the capillary zone electrophoresis method with glycine buffer is an effective means of achieving proper separation of the proteins in the serum samples.
This example is a study of the reproducibility of results from repeated electrophoretic separations of a single serum sample. Six capillaries were used, and ten runs were performed in each capillary in consecutive manner without intervening treatments of the capillaries, under the conditions described in Example 2. Migration times and peak areas were measured in each electropherogram for each of the five peaks plus an internal standard. The mean values were then calculated for each series of ten runs in a run-to-run comparison for each capillary, and standard deviations and coefficients of variation (the standard deviation divided by the mean) were determined. The results are listed in Tables I and II, where "S.D." denotes the standard deviation, and "%C.V." the coefficient of variation expressed as a percent. The mean values were then compared in a capillary-to-capillary comparison, and overall means were then calculated, together with standard deviations and coefficients of variation. These are listed in Table III. It is evident from all three tables that high reproducilibity and precision was obtained.
TABLE I __________________________________________________________________________ Run-to-Run Comparisons in Individual Capillaries Internal Peak → Standard Albumin Alpha-1 Alpha-2 Beta Gamma __________________________________________________________________________ Capillary No. 1 Number of Samples: 10 Migration Mean 2.11 1.68 1.55 1.41 1.31 1.16 Time (min) S.D. 0.034 0.023 0.021 0.014 0.014 0.008 % C.V. 1.63 1.37 1.37 1.02 1.09 0.7 Peak Mean 19.2 50.9 5.7 7.2 7.1 9.4 Area S.D. 0.2098 0.244 0.19 0.155 0.2 0.108 % C.V. 1.09 0.48 3.33 2.15 2.82 1.15 Capillary No. 2 Number of Samples: 10 Migration Mean 2.17 1.73 1.59 1.44 1.33 1.19 Time (min) S.D. 0.0206 0.0127 0.0082 0.0074 0.0048 0.0042 % C.V. 0.95 0.73 0.51 0.51 0.36 0.35 Peak Mean 18.5 51 5.53 7.54 7.21 9.38 Area S.D. 0.28 0.17 0.068 0.097 0.145 0.181 % C.V. 1.51 0.33 1.24 1.28 2.01 1.93 Capillary No. 3 Number of Samples: 10 Migration Mean 2.18 1.73 1.59 1.44 1.33 1.19 Time (min) S.D. 0.0084 0.0048 0.0048 0.0047 0.0048 0.0042 % C.V. 0.39 0.28 0.3 0.33 0.36 0.35 Peak Mean 18.3 51.1 6 7.6 7 9.1 Area S.D. 0.215 0.294 0.193 0.132 0.132 0.145 % C.V. 1.17 0.57 3.22 1.73 1.88 1.59 __________________________________________________________________________
TABLE II __________________________________________________________________________ Run-to-Run Comparisons in Further Individual Capillaries Internal Peak → Standard Albumin Alpha-1 Alpha-2 Beta Gamma __________________________________________________________________________ Capillary No. 4 Number of Samples: 10 Migration Mean 2.09 1.66 1.53 1.38 1.29 1.15 Time (min) S.D. 0.0597 0.0368 0.03 0.0259 0.0227 0.0195 % C.V. 2.85 2.21 1.96 1.88 1.76 1.69 Peak Mean 19.6 51.8 5.2 7.1 7.1 8.9 Area S.D. 0.129 0.27 0.207 0.123 0.155 0.158 % C.V. 0.66 0.52 3.98 1.73 2.18 1.77 Capillary No. 5 Number of Samples: 10 Migration Mean 2.06 1.65 1.52 1.37 1.27 1.14 Time (min) S.D. 0.0534 0.033 0.028 0.0242 0.0206 0.0171 % C.V. 2.59 2 1.84 1.77 1.62 1.5 Peak Mean 18.4 51.8 5.5 7.4 7.2 8.6 Area S.D. 0.135 0.1197 0.1075 0.1449 0.1354 0.1337 % C.V. 0.73 0.23 1.95 1.96 1.88 1.56 Capillary No. 6 Number of Samples: 10 Migration Mean 2.07 1.67 1.53 1.39 1.29 1.15 Time (min) S.D. 0.0726 0.0334 0.0273 0.0244 0.0208 0.0155 % C.V. 3.51 2 1.78 1.76 1.61 1.35 Peak Mean 18.8 51.2 5.6 7.5 7.2 8.8 Area S.D. 0.137 0.2098 0.1449 0.165 0.1619 0.1287 % C.V. 0.73 0.41 2.59 2.2 2.25 1.46 __________________________________________________________________________
TABLE III __________________________________________________________________________ Capillary-to-Capillary Comparisons Internal Peak → Standard Albumin Alpha-1 Alpha-2 Beta Gamma __________________________________________________________________________Capillaries 1 through 6 Migration Mean 2.11 1.69 1.55 1.41 1.3 1.16 Time (min) S.D. 0.0508 0.035 0.031 0.0302 0.024 0.0216 % C.V. 2.4 2.07 2.02 2.14 1.86 1.86 Peak Mean 18.8 51.3 5.6 7.4 7.1 9 Area S.D. 0.51 0.4 0.26 0.194 0.082 0.327 % C.V. 2.71 0.78 4.71 2.62 1.15 3.62 __________________________________________________________________________
The foregoing is offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that the operating conditions, materials, procedural steps and other parameters of the system described herein may be further modified or substituted in various ways without departing from the spirit and scope of the invention.
Claims (18)
1. A method of separating a mixture of proteins in a liquid sample, said method comprising electrophoretically passing said sample through a capillary filled with an alkaline solution of an amino acid .Iadd.at a sufficient concentration to be effective as a buffering agent, and in which said amino acid is the sole buffering agent in said alkaline solution.Iaddend., by imposing an electric field across said capillary, wherein said capillary has an inner surface and said inner surface is uncoated.
2. A method in accordance with claim 1 in which said amino acid is an α-amino acid.
3. A method in accordance with claim 1 in which said amino acid is a member selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, proline, aspartate, glutamate, arginine, threonine and glutamine.
4. A method in accordance with claim 1 in which said amino acid is a member selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine and proline.
5. A method in accordance with claim 1 in which said amino acid is a member selected from the group consisting of glycine, alanine, valine, leucine and isoleucine.
6. A method in accordance with claim 1 in which said amino acid is glycine.
7. A method in accordance with claim 1 in which said alkane solution is free of borate ion and phosphate ion.
8. A method in accordance with claim 1 in which said alkaline solution has a pH of from about 8 to about 11.
9. A method in accordance with claim 1 in which said akaline solution has a pH of from about 9 to about 10.
10. A method in accordance with claim 1 in which said amino acid constitutes from about 10 mM to about 500 mM of said alkaline solution.
11. A method in accordance with claim 1 in which said amino acid constitutes from about 20 mM to about 200 mM of said alkaline solution.
12. A method in accordance with claim 1 in which said capillary has an internal diameter of less than about 200 microns.
13. A method in accordance with claim 1 in which said capillary has an internal diameter of from about 10 microns to about 100 microns.
14. A method in accordance with claim 1 in which said electric field is achieved by applying a voltage of at least about 50 volts per centimeter of capillary length across said capillary.
15. A method in accordance with claim 1 in which said electric field is achieved by applying a voltage of from about 100 to about 1,000 volts per centimeter of capillary length across said capillary.
16. A method in accordance with claim 1 in which said capillary is of a silica-containing material.
17. A method in accordance with claim 1 in which said capillary is a fused silica capillary.
18. A method in accordance with claim 1 in which said capillary is a fused silica capillary having an inner surface of exposed silica.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/975,179 USRE36011E (en) | 1996-02-29 | 1997-11-20 | Protein separations by capillary electrophoresis using amino acid-containing buffers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/610,105 US5660701A (en) | 1996-02-29 | 1996-02-29 | Protein separations by capillary electrophoresis using amino acid-containing buffers |
US08/975,179 USRE36011E (en) | 1996-02-29 | 1997-11-20 | Protein separations by capillary electrophoresis using amino acid-containing buffers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/610,105 Reissue US5660701A (en) | 1996-02-29 | 1996-02-29 | Protein separations by capillary electrophoresis using amino acid-containing buffers |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE36011E true USRE36011E (en) | 1998-12-29 |
Family
ID=24443677
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/610,105 Ceased US5660701A (en) | 1996-02-29 | 1996-02-29 | Protein separations by capillary electrophoresis using amino acid-containing buffers |
US08/975,179 Expired - Lifetime USRE36011E (en) | 1996-02-29 | 1997-11-20 | Protein separations by capillary electrophoresis using amino acid-containing buffers |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/610,105 Ceased US5660701A (en) | 1996-02-29 | 1996-02-29 | Protein separations by capillary electrophoresis using amino acid-containing buffers |
Country Status (7)
Country | Link |
---|---|
US (2) | US5660701A (en) |
EP (1) | EP0832428A1 (en) |
JP (1) | JPH10507004A (en) |
CN (1) | CN1185836A (en) |
AU (1) | AU701982B2 (en) |
CA (1) | CA2207541A1 (en) |
WO (1) | WO1997032204A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6278020B1 (en) | 1993-11-03 | 2001-08-21 | The Associated Octel Company Limited | Alkylation of amino acids |
US6471841B1 (en) * | 1997-04-04 | 2002-10-29 | Caliper Technologies Corp. | Methods and systems for enhanced fluid transport |
US20020162744A1 (en) * | 2001-01-19 | 2002-11-07 | Georges Nouadje | Capillary electrophoresis systems and additives |
US20050274616A1 (en) * | 2004-05-10 | 2005-12-15 | Sebia | Method for separating proteins by capillary electrophoresis and buffer compositions for capillary electrophoresis |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849486A (en) | 1993-11-01 | 1998-12-15 | Nanogen, Inc. | Methods for hybridization analysis utilizing electrically controlled hybridization |
US5605662A (en) | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
US6017696A (en) | 1993-11-01 | 2000-01-25 | Nanogen, Inc. | Methods for electronic stringency control for molecular biological analysis and diagnostics |
US6051380A (en) * | 1993-11-01 | 2000-04-18 | Nanogen, Inc. | Methods and procedures for molecular biological analysis and diagnostics |
US7172864B1 (en) | 1993-11-01 | 2007-02-06 | Nanogen | Methods for electronically-controlled enzymatic reactions |
US7314708B1 (en) * | 1998-08-04 | 2008-01-01 | Nanogen, Inc. | Method and apparatus for electronic synthesis of molecular structures |
US7101661B1 (en) | 1993-11-01 | 2006-09-05 | Nanogen, Inc. | Apparatus for active programmable matrix devices |
US6225059B1 (en) | 1993-11-01 | 2001-05-01 | Nanogen, Inc. | Advanced active electronic devices including collection electrodes for molecular biological analysis and diagnostics |
US6309602B1 (en) | 1993-11-01 | 2001-10-30 | Nanogen, Inc. | Stacked, reconfigurable system for electrophoretic transport of charged materials |
US7582421B2 (en) * | 1993-11-01 | 2009-09-01 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using a bioelectronic microchip |
US6331274B1 (en) | 1993-11-01 | 2001-12-18 | Nanogen, Inc. | Advanced active circuits and devices for molecular biological analysis and diagnostics |
US20040077074A1 (en) * | 1993-11-01 | 2004-04-22 | Nanogen, Inc. | Multi-chambered analysis device |
US7857957B2 (en) | 1994-07-07 | 2010-12-28 | Gamida For Life B.V. | Integrated portable biological detection system |
US6379897B1 (en) * | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
US6403367B1 (en) | 1994-07-07 | 2002-06-11 | Nanogen, Inc. | Integrated portable biological detection system |
US20040086917A1 (en) * | 1995-09-27 | 2004-05-06 | Nanogen, Inc. | Methods for electronic fluorescent perturbation for analysis and electronic perturbation catalysis for synthesis |
DE19741715A1 (en) * | 1997-09-22 | 1999-03-25 | Hoechst Ag | New pentopyranosyl nucleoside compounds |
US6156179A (en) * | 1998-07-09 | 2000-12-05 | Bio-Rad Laboratories | Computer directed identification of paraproteins |
CN1296703C (en) * | 1999-02-02 | 2007-01-24 | 卡钳生命科学股份有限公司 | Methods, devices and systems for characterizing proteins |
US20050027111A1 (en) * | 1999-02-02 | 2005-02-03 | Caliper Life Sciences, Inc. | Methods, devices and systems for characterizing proteins |
FR2819889B1 (en) * | 2001-01-19 | 2003-08-01 | Sebia Sa | METHOD OF CAPILLARY ELECTROPHORESIS IN FREE ALKALINE PH SOLUTION |
US7601493B2 (en) * | 2002-07-26 | 2009-10-13 | Nanogen, Inc. | Methods and apparatus for screening and detecting multiple genetic mutations |
US7645293B2 (en) | 2004-04-21 | 2010-01-12 | United States Surgical Corporation | Suture anchor installation system and method |
CN100337113C (en) * | 2004-04-30 | 2007-09-12 | 首都师范大学 | Acidic capillary electrophoresis identification method for high molecular weight glutelin subunit of wheat |
US7314542B2 (en) * | 2004-09-23 | 2008-01-01 | Nanogen, Inc. | Methods and materials for optimization of electronic transportation and hybridization reactions |
KR100978055B1 (en) * | 2008-08-25 | 2010-08-25 | 한국과학기술연구원 | Improved Detection Sensitivity of Capillary Electrophoresis Using an Improved Sample Injection Method |
CN101915696B (en) * | 2010-07-07 | 2014-08-13 | 邯郸开发区奥泰克生物科技有限公司 | Method for preparing capillary inner wall coating |
WO2013155634A1 (en) | 2012-04-19 | 2013-10-24 | Jiaqi Wu | Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates |
US20150093757A1 (en) * | 2013-09-27 | 2015-04-02 | Protein Simple | Methods. apparatus and systems for detection of total protein using capillary electrophoresis |
EP3402894A1 (en) * | 2016-01-15 | 2018-11-21 | Pierce Biotechnology, Inc. | Protein preparation by reduction of oxidized methionines |
KR20220134595A (en) * | 2020-01-27 | 2022-10-05 | 브리스톨-마이어스 스큅 컴퍼니 | isoelectric focusing sample matrix |
CN114544738A (en) * | 2022-02-15 | 2022-05-27 | 河北北方学院 | a running buffer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221447A (en) * | 1991-12-06 | 1993-06-22 | Bio-Rad Laboratories, Inc. | Hydrophilic polymer coating of high pH stability for silica surfaces for suppression of electroendomosis and solute adsorption |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE314227B (en) * | 1964-08-26 | 1969-09-01 | Lkb Produkter Ab | |
DE2656801C2 (en) * | 1976-12-15 | 1983-11-17 | Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Process for the production of carrier ampholytes for the isoelectric focusing of high molecular weight amphoteric substances |
DE2809977A1 (en) * | 1978-03-08 | 1979-09-13 | Serva Entwicklungslabor V Grot | Di:amino-mono:- and poly:carboxylic acid mixt. - prepd. from di:amine mixt. and acrylic acid homologue mixt. and used as isoelectric focussing carrier ampholyte |
US4292154A (en) * | 1979-11-07 | 1981-09-29 | Gelman Sciences, Inc. | Buffer composition and method for the electrophoretic separation of proteins |
DE3883288T2 (en) * | 1987-05-27 | 1993-12-09 | Abbott Lab | Polycation buffer solutions and methods for gel electrophoresis of nucleic acids. |
US4857163A (en) * | 1987-07-17 | 1989-08-15 | Beckman Instruments, Inc. | High resolution electrophoretic gel and method for separating serum proteins |
-
1996
- 1996-02-29 US US08/610,105 patent/US5660701A/en not_active Ceased
-
1997
- 1997-02-26 CA CA002207541A patent/CA2207541A1/en not_active Abandoned
- 1997-02-26 CN CN97190003A patent/CN1185836A/en active Pending
- 1997-02-26 WO PCT/US1997/002179 patent/WO1997032204A1/en not_active Application Discontinuation
- 1997-02-26 EP EP97907607A patent/EP0832428A1/en not_active Withdrawn
- 1997-02-26 AU AU19570/97A patent/AU701982B2/en not_active Ceased
- 1997-02-26 JP JP9521519A patent/JPH10507004A/en active Pending
- 1997-11-20 US US08/975,179 patent/USRE36011E/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221447A (en) * | 1991-12-06 | 1993-06-22 | Bio-Rad Laboratories, Inc. | Hydrophilic polymer coating of high pH stability for silica surfaces for suppression of electroendomosis and solute adsorption |
Non-Patent Citations (4)
Title |
---|
Lei Wang et al, "Study on the reproducibility of migration time from dipeptides in high performance capillary electrophoresis" SEPU, 11(4) (1993) 207-209. |
Lei Wang et al, Study on the reproducibility of migration time from dipeptides in high performance capillary electrophoresis SEPU, 11(4) (1993) 207 209. * |
Nava Cohen and Eli Grushka, "Controlling electroosmotic flow in capillary zone electrophoresis" Journal of Chromatography A, 678 (1994) 167-175. |
Nava Cohen and Eli Grushka, Controlling electroosmotic flow in capillary zone electrophoresis Journal of Chromatography A, 678 (1994) 167 175. * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6278020B1 (en) | 1993-11-03 | 2001-08-21 | The Associated Octel Company Limited | Alkylation of amino acids |
US6471841B1 (en) * | 1997-04-04 | 2002-10-29 | Caliper Technologies Corp. | Methods and systems for enhanced fluid transport |
US20020162744A1 (en) * | 2001-01-19 | 2002-11-07 | Georges Nouadje | Capillary electrophoresis systems and additives |
US7297244B2 (en) | 2001-01-19 | 2007-11-20 | Sebia | Capillary electrophoresis systems and additives |
US20050274616A1 (en) * | 2004-05-10 | 2005-12-15 | Sebia | Method for separating proteins by capillary electrophoresis and buffer compositions for capillary electrophoresis |
US7906001B2 (en) | 2004-05-10 | 2011-03-15 | Sebia | Method for separating proteins by capillary electrophoresis and buffer compositions for capillary electrophoresis |
Also Published As
Publication number | Publication date |
---|---|
AU701982B2 (en) | 1999-02-11 |
EP0832428A1 (en) | 1998-04-01 |
CN1185836A (en) | 1998-06-24 |
AU1957097A (en) | 1997-09-16 |
CA2207541A1 (en) | 1997-08-29 |
WO1997032204A1 (en) | 1997-09-04 |
JPH10507004A (en) | 1998-07-07 |
US5660701A (en) | 1997-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE36011E (en) | Protein separations by capillary electrophoresis using amino acid-containing buffers | |
Adamson et al. | Rules relating electrophoretic mobility, charge and molecular size of peptides and proteins | |
Grossman et al. | Effect of buffer pH and peptide composition on the selectivity of peptide separations by capillary zone electrophoresis | |
JP2731034B2 (en) | Use of zwitterions to move isoelectrofocused ampholyte zones. | |
US5120413A (en) | Analysis of samples utilzing capillary electrophoresis | |
Otsuka et al. | Effects of methanol and urea on optical resolution of phenylthiohydantion‐DL‐amino acids by micellar electrokinetic chromatography with sodium N‐dodecanoyl‐L‐valinate | |
Corradini et al. | Electrophoresis of proteins in uncoated capillaries with amines and amino sugars as electrolyte additives | |
Righetti et al. | Current trends in capillary isoelectric focusing of proteins | |
Janini et al. | Electrokinetic chromatography in suppressed electroosmotic flow environment: Use of a charged cyclodextrin for the separation of enantiomers and geometric isomers | |
US3692654A (en) | Electrophoretic process | |
EP0556352B1 (en) | Capillary zone electrophoresis using dynamic coating buffers | |
Smith et al. | Capillary isotachophoresis with UV and tandem mass spectrometric detection for peptides and proteins | |
Guttman et al. | Capillary sodium dodecyl sulfate gel electrophoresis of proteins II. On the Ferguson method in polyethylene oxide gels | |
Corradini et al. | N, N, N′, N′‐Tetramethyl‐1, 3‐butanediamine as effective running electrolyte additive for efficient electrophoretic separation of basic proteins in bare fused‐silica capillaries | |
Zeece | Capillary electrophoresis: a new analytical tool for food science | |
Cross et al. | Salt effects in capillary zone electrophoresis I. Dependence of electrophoretic mobilities upon the hydrodynamic radius | |
Koval et al. | Determination of pKa values of diastereomers of phosphinic pseudopeptides by CZE | |
Bolger et al. | Performance of uncoated and coated capillaries in free zone electrophoresis and isoelectric focusing of proteins | |
US4911808A (en) | Mobilization of focused protein zones by ion introduction | |
AU641607B2 (en) | Capillary gels formed by spatially progressive polymerization using migrating initiator | |
Karamanos et al. | State‐of‐the‐art of capillary electrophoresis with application to the area of glycoconjugates | |
Pande et al. | Optimization and validation of analytical conditions for bovine serum albumin using capillary electrophoresis | |
US20020195341A1 (en) | Alkaline pH, free solution capillary electrophoresis method | |
Teshima et al. | [12] Capillary electrophoresis analysis of recombinant proteins | |
AU4374001A (en) | Separation of antithrombin III variants by cyclodextrin-modified micellar electrokinetic chromatography |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |